193 completed, 42 recruiting, 36 terminated, 34 active not recruiting. 219 Phase 2, 134 Phase 1, 70 Phase 3, 3 Not applicable, 3 Phase 4.
Follow Bendamustine Hydrochloride: new trials by email Literature Review of Bendamustine Hydrochloride trials Research Report on Bendamustine Hydrochloride
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CD30 CAR-T Cells for Low Risk Relapsed Classical Hodgkin Lymphoma CD30+ CAR T-cells, Bendamustin, Fludarabine - Classical Hodgkin Lymphoma | Phase 1 | Not yet recruiting | New York Medical College | 12 | 2026-10-01 | 2026-05-20 |
| Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion in Chimeric Antigen Receptor T-cell Immunotherapy (CAR-T): a Randomized Trial. bendamustine hydrochloride, Cyclophosphamide, Fludarabine - B-cell Lymphoma | Phase 2 | Recruiting | Swiss Cancer Institute | 92 | 2026-09-24 | 2026-10-16 |
| Autoimmune Cytopenia Elimination by Chimeric Antigen Receptor T-cell Therapy AZD0120, Bendamustin - Cytopenia | Phase 1 | Not yet recruiting | Saurabh Dahiya | 16 | 2026-09-01 | 2026-08-27 |
| A Clinical Trial to Evaluate the Efficacy and Safety of TQB3909 Tablets Versus Investigator's Choice in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) TQB3909 Tablets, Bendamustine Injection, Rituximab injection - Small Lymphocytic Lymppho, Relapsed/Refractory Chronic Lymphocytic Leukemia | Phase 3 | Not yet recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 128 | 2026-08-01 | 2026-08-11 |
| A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma Orelabrutinib, obinutuzumab, Lenalidomide - Follicular Lymphoma ( FL) | Phase 3 | Not yet recruiting | Ruijin Hospital | 652 | 2026-07-01 | 2026-07-22 |
| A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) MK-1045, Rituximab, Rituximab biosimilar - Follicular Lymphoma | Phase 2 / Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 960 | 2026-06-22 | 2026-10-15 |
| Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma Bendamustine, Pralatrexate, Bone Marrow Aspiration - Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 50 | 2026-04-27 | 2026-05-11 |
| Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis TRX319, Bendamustine - Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS) | Phase 1 / Phase 2 | Recruiting | Tr1X, Inc. | 39 | 2026-03-01 | 2026-09-21 |
| A Phase II Clinical Study of Zanubrutinib Combined With Four Cycles of CD20 Monoclonal Antibody and Reduced-Dose Bendamustine in the Treatment of Untreated Waldenström Macroglobulinemia Zaunbrutinib, Bendamustine and Rituximab for induction therapy, Zanubrutinib mono therapy for maintenance treatment - Waldenström Macroglobulinemia (WM) | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 43 | 2025-12-30 | 2025-12-02 |
| A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma Rocbrutinib, Bendamustine, Rituximab - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 | Recruiting | Guangzhou Lupeng Pharmaceutical Company LTD. | 150 | 2025-11-27 | 2025-12-16 |
| Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT Assessment Bendamustine + anti-CD20 monoclonal antibody/orelabrutinib + anti-CD20 monoclonal antibody - Mantle Cell Lymphoma | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 45 | 2025-10-01 | 2025-10-03 |
| A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6) DZD8586, Bendamustine, Idelalisib - Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 3 | Recruiting | Dizal Pharmaceuticals | 250 | 2025-09-08 | 2026-06-03 |
| Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia Ibrutinib, Bendamustine, Rituximab - Waldenström Macroglobulinemia (WM) | Phase 1 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 21 | 2025-09-01 | 2025-09-11 |
| Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL Orelabrutinib, Zebetuzumab, Lenalidomide - Marginal Zone Lymphoma(MZL) | Phase 2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 169 | 2025-08-14 | 2025-10-06 |
| A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4) Golcadomide, Rituximab, Lenalidomide - Follicular Lymphoma | Phase 3 | Recruiting | Celgene | 400 | 2025-07-28 | 2026-05-20 |
| Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma zanubrutinib, bendamustine, and obinutuzumab - Follicular Lymphoma, Treatment Naive | Not applicable | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 15 | 2025-07-15 | 2025-08-17 |
| Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study Zanubrutinib, Obinutuzumab, Bendamustine - Chronic Lymphocytic Leukemia | Phase 2 | Not yet recruiting | The First Hospital of Jilin University | 30 | 2025-06-15 | 2025-06-04 |
| MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma Bendamustine, Rituximab - Lymphoma, Indolent Non-hodgkin Lymphoma | Phase 2 | Not yet recruiting | Fox Chase Cancer Center | 24 | 2025-06-01 | 2025-01-06 |
| A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors BGB-16673, Bendamustine, Rituximab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Active not recruiting | BeOne Medicines | 153 | 2025-05-29 | 2026-08-24 |
| A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype Duvelisib, Gemcitabine, Bendamustine - Lymphoma | Phase 3 | Recruiting | SecuraBio | 124 | 2025-05-19 | 2026-04-06 |
Showing 20 of 376. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (88) · Lymphoma, Non-Hodgkin (72) · Lymphoma (63) · Lymphoma, Follicular (61) · Lymphoma, Mantle-Cell (58) · Lymphoma, Large B-Cell, Diffuse (40) · Multiple Myeloma (36) · Hodgkin Disease (32) · Recurrence (30) · Lymphoma, B-Cell, Marginal Zone (28) · Lymphoma, B-Cell (19) · Leukemia (18) · Waldenstrom Macroglobulinemia (14) · Neoplasms (13) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (12)
Hoffmann-La Roche (15) · M.D. Anderson Cancer Center (13) · German CLL Study Group (11) · Cephalon (8) · Fate Therapeutics (8) · National Cancer Institute (NCI) (8) · St. Petersburg State Pavlov Medical University (8) · Fondazione Italiana Linfomi - ETS (7) · UNC Lineberger Comprehensive Cancer Center (6) · Fred Hutchinson Cancer Center (5) · Genentech, Inc. (5) · Institute of Hematology & Blood Diseases Hospital, China (5) · SymBio Pharmaceuticals (5) · The Lymphoma Academic Research Organisation (5) · Celgene (4)
United States (214) · Italy (62) · Germany (61) · France (56) · Spain (51) · China (50) · Canada (46) · United Kingdom (45) · Australia (39) · Poland (37) · Belgium (35) · South Korea (33) · Czechia (30) · Russia (30) · Israel (24)
Julie Chang, MD (4) · Natalie Grover, MD (4) · Paula Cramer, Dr. med. (4) · Ajay Gopal (2) · Armando Santoro, MD (2)
PMID 38620092, PMID 31050355, PMID 32126141, PMID 34086865, PMID 19860608, PMID 20594195, PMID 20626754, PMID 21239695, PMID 21816833, PMID 21844497, PMID 22331940, PMID 22451423, PMID 22571691, PMID 22869884, PMID 23109692, PMID 23248254, PMID 23401442, PMID 23430121, PMID 23433739, PMID 23592273, PMID 23753028, PMID 23843495, PMID 23955074, PMID 24359243, PMID 24591201, PMID 24925211, PMID 25145344, PMID 25355819, PMID 25398832, PMID 25630297, PMID 25769620, PMID 25911554, PMID 26239087, PMID 26331432, PMID 26377597, PMID 26643449, PMID 26655421, PMID 26659915, PMID 26729345, PMID 26875824, PMID 26913697, PMID 27018242, PMID 27029228, PMID 27222473, PMID 27233802, PMID 27345636, PMID 27354719, PMID 27382096, PMID 27442600, PMID 27695295
2015 (8), 2014 (7), 2023 (7), 2009 (5), 2016 (5), P30CA012197 (3), U10CA180821 (3), 2017 (2), 2018 (2), 2019 (2), P30CA015704 (2), P30CA138292 (2), U10CA031946 (2), U10CA032102 (2), U10CA180820 (2)